Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 503-507

  Amagai, Yosuke ^a   Matsumoto, Mitsunobu ^a   Hojo, Kanji ^a   Iguchi, Motofumi ^a   Wada, Tooru ^a   Tanaka, Hidekazu ^a   Ide, Nobuyuki ^a   Kato, Akira ^a   Shichijo, Michitaka ^a   Abe, Kenji ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Combination therapy; IL 2; Pulmonary metastasis; Renal cell carcinoma; Sorafenib

Indexed keywords

IMUNACE; RECOMBINANT INTERLEUKIN 2; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INTERLEUKIN 2; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; KIDNEY CARCINOMA; LUNG METASTASIS; LUNG RESECTION; METASTASIS INHIBITION; MOUSE; NEPHRECTOMY; NONHUMAN; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; KIDNEY TUMOR; LUNG TUMOR; METASTASIS; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEPHRECTOMY; PYRIDINES; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 77953458187     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp200     Document Type: Article

References (20)

1. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
3. Rouviére O, Bouvier R, Négrier S, Badet L, Lyonnet D. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? Nat Clin Pract Oncol 2006;3:200-13.
4. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998;338:1272-8.
5. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
6. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80:1198-220.
7. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
8. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
9. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
10. Lane BR, Rini BI, Novick AC, Campbell SC. Targeted molecular therapy for renal cell carcinoma. Urology 2007;69:3-10.
11. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
12. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
13. Iguchi M, Matsumoto M, Hojo K, Wada T, Matsuo Y, Arimura A, et al. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Jpn J Clin Oncol 2009;39:303-9.
14. Stockley IH. Drug Interactions. 3rd edn. Blackwell Scientific Publications, Oxford 1994.
15. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
16. Thomas H, Vallis KA, Williams G, Waxman J. Ascites induced by interleukin-2 in the treatment of renal cancer. Br J Urol 1990;65:303-5.
17. Kobori G, Maegawa M, Ushida H, Maekawa S, Inoue K, Kaneko Y, et al. Two cases of renal cell carcinoma with ascites after interleukin-2 therapy. Hinyokika Kiyo 2002;48:455-7.
18. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007;28:297-321.
19. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
20. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.